BioNTech, the German biotechnology giant, has announced an acquisition of CureVac—a fellow biotech company—valued at a staggering $1.25 billion. This bold move is strategically designed to bolster their collective efforts in the realm of cancer research. As part of the deal, CureVac investors will receive $5.46 in BioNTech shares for each of their CureVac shares, […]
Category: BioNTech
The Impact of Alternative CGT Manufacturing Models
As the world of biotechnology continues to evolve, the pharmaceutical industry in Spain is charting a bold new course. A recent panel discussion revealed the growing trend of in-house academic chimeric antigen receptor (CAR)-T cell manufacturing, fueled by regulatory flexibility and a commitment to reducing costs. This shift towards a more integrated ‘bench-to-bedside’ approach is […]
